DH vs. QTRX, AUNA, LYEL, EYPT, MLYS, PHAR, MLAB, ZYME, SVRA, and SLN
Should you be buying Definitive Healthcare stock or one of its competitors? The main competitors of Definitive Healthcare include Quanterix (QTRX), Auna (AUNA), Lyell Immunopharma (LYEL), EyePoint Pharmaceuticals (EYPT), Mineralys Therapeutics (MLYS), Pharming Group (PHAR), Mesa Laboratories (MLAB), Zymeworks (ZYME), Savara (SVRA), and Silence Therapeutics (SLN). These companies are all part of the "medical" sector.
Definitive Healthcare (NASDAQ:DH) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Quanterix received 245 more outperform votes than Definitive Healthcare when rated by MarketBeat users. Likewise, 61.66% of users gave Quanterix an outperform vote while only 30.99% of users gave Definitive Healthcare an outperform vote.
Quanterix has a net margin of -28.82% compared to Definitive Healthcare's net margin of -78.16%. Definitive Healthcare's return on equity of 0.51% beat Quanterix's return on equity.
In the previous week, Quanterix had 3 more articles in the media than Definitive Healthcare. MarketBeat recorded 17 mentions for Quanterix and 14 mentions for Definitive Healthcare. Quanterix's average media sentiment score of 1.07 beat Definitive Healthcare's score of -0.08 indicating that Quanterix is being referred to more favorably in the news media.
Definitive Healthcare has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.
98.7% of Definitive Healthcare shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 14.8% of Definitive Healthcare shares are owned by insiders. Comparatively, 6.9% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Quanterix has lower revenue, but higher earnings than Definitive Healthcare. Quanterix is trading at a lower price-to-earnings ratio than Definitive Healthcare, indicating that it is currently the more affordable of the two stocks.
Definitive Healthcare presently has a consensus target price of $9.94, indicating a potential upside of 80.81%. Quanterix has a consensus target price of $30.60, indicating a potential upside of 76.37%. Given Definitive Healthcare's higher possible upside, equities analysts plainly believe Definitive Healthcare is more favorable than Quanterix.
Summary
Quanterix beats Definitive Healthcare on 11 of the 18 factors compared between the two stocks.
Get Definitive Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for DH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Definitive Healthcare Competitors List
Related Companies and Tools
